Posted by Michael Wonder on 24 Nov 2020
Telix new drug application for prostate cancer imaging product accepted by US FDA
24 November 2020 - Telix Pharmaceuticals announces new drug application for TLX591-CDx.
Telix Pharmaceuticals announces new drug application for TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11), a radiopharmaceutical targeting prostate-specific membrane antigen for the imaging of prostate cancer using positron emission tomography, has been accepted for filing by the United States FDA.
